Xarelto不良反应

Rivaroxaban (Xarelto) is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson. It is a highly selective oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Rivaroxaban (Xarelto) does not inhibit thrombin and has not been shown to have an effect on platelets. A dose-dependent inhibitory effect of rivaroxaban (Xarelto) on factor xa activity has been observed in humans. 

Adverse reactions are drug effects that occur at therapeutic doses and are unrelated to the therapeutic purpose and are generally unavoidable. Rivaroxaban (Xarelto, Xarelto) adverse reactions: The most common adverse reaction of rivaroxaban (Xarelto, Xarelto) is bleeding. Anticoagulant drugs all have bleeding risks, but the risk of clinical major bleeding is relatively low. Hemorrhagic complications may manifest as weakness, weakness, pallor, dizziness, headache, or unexplained swelling. Therefore, the possibility of bleeding should be considered when evaluating patients taking anticoagulants. Secondly, some patients may also experience allergic reactions, such as urticaria, dermatitis, etc. There are also some patients who may have a certain impact on liver and kidney function, causing an increase in creatinine and transaminases. Some relatively rare adverse reactions include abnormal blood vessels, abnormal number of platelets, changes in coagulation function, etc. Rivaroxaban (Xarelto, Xarelto) other adverse reactions: agranulocytosis, anaphylactic shock, anaphylaxis, angioedema, cerebral hemorrhage, cholestasis, decreased hemoglobin, DRESS syndrome (with eosinophils Increased drug rash and systemic symptoms), injection site hematoma, hemiplegia, hematuria, hepatitis, liver damage, allergic reactions, intracranial hemorrhage, jaundice, retroperitoneal hemorrhage, spinal hematoma, Stevens-Johnson syndrome, subdural hematoma, thrombocytopenia.